Title : Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).

Pub. Date : 2015 Aug 27

PMID : 26313445






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This Phase III study (COMMAND-4; AI444-042) evaluated the efficacy and safety of daclatasvir (DCV), a pan-genotypic HCV NS5A inhibitor, with pegylated interferon-alpha2a/ribavirin (PEG-IFN/RBV) in treatment-naive patients with HCV GT4 infection. daclatasvir interferon alpha 2 Homo sapiens